EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral Blood Neutrophils and Monocytes Predict Disease Progression in Stage III Melanoma Patients Treated With Anti Programmed Cell Death Protein‐1 (PD‐1) Inhibitors

Annagioia Ventrici iD, Luca Modestino iD, Leonardo Cristinziano iD, Francesco Caraglia, Ilaria Spatocco, Carlo Gabriele Tocchetti, Teresa Troiani, Remo Poto iD, Paola de Candia, Gilda Varricchi, Maria Rosaria Galdiero iD

Journal of Immunology Research · 2026-01 · 2026 (1)

DOI: 10.1155/jimr/3825424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunology Research, online erschienen am 22.03.2026. Verfasst von Annagioia Ventrici und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medical Sciences (DiSMeT), University of Naples "Federico II", Naples, Italy, unina.it. Hauptthemen laut MEDLINE: Melanoma, Neutrophils, Monocytes, Immune Checkpoint Inhibitors. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Universita degli Studi di Napoli Federico II, CRUI-CARE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma is a global health issue, with an increasing incidence in recent years. Immune checkpoint inhibitors (ICIs, e.g., antiprogrammed cell death protein 1 [PD‐1]) and targeted therapies (e.g., BRAF/MEK inhibitors) have revolutionized treatment for melanoma patients (MPs), but prognostic markers of drug response and disease progression remain elusive. We conducted a prospective baseline and follow‐up study to investigate peripheral blood neutrophils and monocytes as immune biomarkers in stage III MPs receiving either anti‐PD‐1 therapy or B‐type rapidly accelerated fibrosarcoma (BRAF)/mitogen‐activated protein kinase kinase (MEK) inhibitors. Sixty‐four stage III MPs were prospectively recruited, of whom 42 received anti‐PD‐1 therapy, and 22 received BRAF/MEK inhibitors. Neutrophils and monocytes were isolated and analyzed by flow cytometry, while plasma concentrations of neutrophil‐related mediators and neutrophil extracellular trap (NET) biomarkers were measured by enzyme‐linked immunosorbent assay (ELISA). In MPs, neutrophils displayed an activated phenotype (CD16 + CD62L − ), and both neutrophils and monocytes had higher PD‐1 ligand (PD‐L1) expression, compared with healthy controls (HCs). Importantly, higher percentages of CD16 + CD62L – and PD‐L1 + neutrophils and PD‐L1 + monocytes—but not higher levels of neutrophil‐related mediators and NET biomarkers—were associated with disease progression only in MPs treated with anti‐PD‐1 therapy but not in those treated with BRAF/MEK inhibitors. This study reveals that a specific neutrophil and monocyte phenotype can predict clinical responses exclusively in ICI‐treated patients, highlighting their potential as prognostic biomarkers before starting the immune checkpoint inhibition in melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeutrophilsMonocytesImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorHumansFemaleDisease ProgressionMaleNeoplasm StagingMiddle AgedAgedPrognosisAdultProspective StudiesBiomarkers, TumorProtein Kinase Inhibitors

Stichwörter der Autor:innen

checkpoint inhibitorsinnate immunitymelanomamonocytesneutrophils

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, humanBiomarkers, TumorProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Translational Medical Sciences (DiSMeT), University of Naples "Federico II", Naples, Italy, unina.it.
  • Department of Internal Medicine and Clinical Immunology, University Hospital of Naples "Federico II", Naples, Italy, unina.it.
  • Center for Basic and Clinical Immunology Research (CISI), University of Naples "Federico II", Naples, Italy, unina.it.
  • Oncoematology Unit, Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy, unina2.it.
  • Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Naples, 80131, Italy, unina.it.

ORCID-Profile: Annagioia Ventrici, Luca Modestino, Leonardo Cristinziano, Remo Poto, Maria Rosaria Galdiero

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Universita degli Studi di Napoli Federico II
  • CRUI-CARE

Zitieren

APA

Ventrici, A., Modestino, L., Cristinziano, L., Caraglia, F., Spatocco, I., Tocchetti, C. G., Troiani, T., Poto, R., de Candia, P., Varricchi, G., & Galdiero, M. R. (2026). Peripheral Blood Neutrophils and Monocytes Predict Disease Progression in Stage III Melanoma Patients Treated With Anti Programmed Cell Death Protein‐1 (PD‐1) Inhibitors. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/3825424

Vancouver

Ventrici A, Modestino L, Cristinziano L, Caraglia F, Spatocco I, Tocchetti CG, et al. Peripheral Blood Neutrophils and Monocytes Predict Disease Progression in Stage III Melanoma Patients Treated With Anti Programmed Cell Death Protein‐1 (PD‐1) Inhibitors. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/3825424

BibTeX
@article{Ventrici2026,
  author = {Ventrici, Annagioia and Modestino, Luca and Cristinziano, Leonardo and Caraglia, Francesco and Spatocco, Ilaria and Tocchetti, Carlo Gabriele and Troiani, Teresa and Poto, Remo and de Candia, Paola and Varricchi, Gilda and Galdiero, Maria Rosaria},
  title = {Peripheral Blood Neutrophils and Monocytes Predict Disease Progression in Stage III Melanoma Patients Treated With Anti Programmed Cell Death Protein‐1 (PD‐1) Inhibitors},
  journal = {Journal of Immunology Research},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/jimr/3825424}
}
Kostenlos starten →